ACC: Medrad focuses on thrombosis with new products, JETSTENT study
“Thrombosis matters” was the theme being promoted this year at the American College of Cardiology (ACC) annual conference in Atlanta by Medrad Interventional / Possis, the Indianola, Pa.-based medical device and cardiovascular applications provider.
“One of the primary predictors of poor outcome for an MI patient is whether he or she has thrombus and how large the thrombus is,” explained Alan Kaeding, marketing manager of communications and services, who noted that the company was promoting a JETSTENT study that utilized their thrombectomy system.
The AngioJet Thrombectomy System works inside the vascular system to remove thrombus, said Medrad. The technology was cleared for human use in 1996 and the study--which compared PCI with thrombectomy to PCI alone in acute MI patients--was released during a late-breaking trials session at ACC.
Kaeding said that Medrad is suggesting that addressing thrombosis would improve patient outcomes.
The JETSTENT study enrolled 501 patients at eight sites across Europe and South America between December 2005 and September 2009 to determine how use of a rheolytic thrombectomy system would affect myocardial reperfusion and clinical outcomes for patients with acute STEMI.
The study found that significantly more patients receiving rheolytic thrombectomy in addition to direct stenting experienced resolution of their STEMI in the designated time frame (30 to 45 minutes post-procedure) than those patients receiving stenting alone (85.8 vs 78.8 percent, respectively).
The researchers also found a significant decrease in major cardiovascular adverse events both at one month and at six months for patients randomized to receive rheolytic thrombectomy than patients in the direct stenting alone arm.
Lead researcher David Antoniucci, MD, head of the division of cardiology at Careggi Hospital in Florence, Italy, said that the results "support the routine use of thrombectomy in patients with acute ST-segment elevation heart attack and evidence of thrombus."
In addition to the JETSTENT study, Medrad showcased its GuardDog occlusion balloon, and three addition products waiting for FDA approval. These products include the Fetch 2 aspiration catheter, an enhancement of the existing Fetch catheter, noted Kaeding, as well as two peripheral catheters that offer a variety of new features over the existing peripheral catheters, he said. “We hope to receive word on these products soon.”
“One of the primary predictors of poor outcome for an MI patient is whether he or she has thrombus and how large the thrombus is,” explained Alan Kaeding, marketing manager of communications and services, who noted that the company was promoting a JETSTENT study that utilized their thrombectomy system.
The AngioJet Thrombectomy System works inside the vascular system to remove thrombus, said Medrad. The technology was cleared for human use in 1996 and the study--which compared PCI with thrombectomy to PCI alone in acute MI patients--was released during a late-breaking trials session at ACC.
Kaeding said that Medrad is suggesting that addressing thrombosis would improve patient outcomes.
The JETSTENT study enrolled 501 patients at eight sites across Europe and South America between December 2005 and September 2009 to determine how use of a rheolytic thrombectomy system would affect myocardial reperfusion and clinical outcomes for patients with acute STEMI.
The study found that significantly more patients receiving rheolytic thrombectomy in addition to direct stenting experienced resolution of their STEMI in the designated time frame (30 to 45 minutes post-procedure) than those patients receiving stenting alone (85.8 vs 78.8 percent, respectively).
The researchers also found a significant decrease in major cardiovascular adverse events both at one month and at six months for patients randomized to receive rheolytic thrombectomy than patients in the direct stenting alone arm.
Lead researcher David Antoniucci, MD, head of the division of cardiology at Careggi Hospital in Florence, Italy, said that the results "support the routine use of thrombectomy in patients with acute ST-segment elevation heart attack and evidence of thrombus."
In addition to the JETSTENT study, Medrad showcased its GuardDog occlusion balloon, and three addition products waiting for FDA approval. These products include the Fetch 2 aspiration catheter, an enhancement of the existing Fetch catheter, noted Kaeding, as well as two peripheral catheters that offer a variety of new features over the existing peripheral catheters, he said. “We hope to receive word on these products soon.”